ASI-222

Subscribe to Selected New Research on ASI-222

10 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: semisynthetic cardiac glycoside; RN given refers to (3beta,5beta)-isomer; structure

Also Known As:

3 beta-O-(4-amino-4,6-dideoxy-beta-D-galactopyranosyl)digitoxigenin; ASI 222; ASI-222 dihydrate; ASI-222 hydrochloride; (3 beta,5 beta)-3-((4-amino-4,6-dideoxy-beta-D-galactopyranosyl)oxy)-14-hydroxycard-20(22)-enolide

Bio-Agent Context: Research Results

Polycyclic Compounds: 58

Related Diseases

1.	Atrioventricular Block 06/01/1994 - "For in vivo studies, ASI-222 was infused at a rate of 1 microgram/kg/min until appearance of third-degree atrioventricular (AV) block or sustained ventricular arrhythmias in 5 conscious (control) and 6 halothane-anesthetized (1.4% end-tidal) dogs" Get all the results and reference details, order at left...
2.	Cardiac Arrhythmias (Arrythmia) 04/01/1990 - "Infusion of ASI-222 progressively reduced sympathetic nerve activity (approximately 55%) through the toxic dose; sympathetic nerve activity remained depressed even through the onset of cardiac arrhythmias" 09/01/1992 - "The vagi were cooled (approximately 4 degrees C) and then either ASI-222 or digoxin was infused i.v. at dose rates which produce cardiac arrhythmias after about 100 min. Saline was infused in a third group" 01/01/1992 - "After we made baseline measurements, we infused either ASI-222 or digoxin intravenously (i.v.) at dose rates that produce cardiac arrhythmias in approximately 100 min (0.7 and 1.2 micrograms/kg/min), respectively" 04/01/1990 - "Digoxin or ASI-222 were infused into anesthetized dogs at dose rates which caused cardiac arrhythmias in about 2 hr. Nerve activities were monitored and recorded by a system of differential amplifiers and by a digital storage oscilloscope" 11/01/1989 - "The effect of i.v. infusion of potassium chloride upon cardiac upon cardiac arrhythmias produced by i.v. infusion of digoxin or ASI-222 in anesthetized dogs was also determined" Get all the results and reference details, order at left...
3.	Stroke (Strokes) 09/01/1979 - "ASI-222 is about three times more potent than digoxin in creasing left ventricular stroke work" 09/01/1979 - "ASI-222 is about three times more potent than digitoxigenin and about twice as potent as digitoxigenin-beta-D-galactose in producing similar increases in the left ventricular stroke work" Get all the results and reference details, order at left...
4.	Ventricular Premature Complexes (Premature Ventricular Contraction) 04/01/1976 - "The occurrence of ventricular ectopic beats was observed at a higher cumulative dose of ASI-222 than for ouabain" Get all the results and reference details, order at left...
5.	Ventricular Tachycardia 12/01/1978 - "Ventricular tachycardia was elicited at a mean dose of digoxin of 0.12 mg/kg, compared with 0.09 mg/kg for ASI-222 (not significant)" Get all the results and reference details, order at left...
9 Diseases and 10 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Halothane (Fluothane)
2.	Digoxin (Digitek)
3.	Potassium Chloride
4.	Ouabain (G Strophanthin)
5.	Metoprolol (Lopressor)
6.	Digitoxigenin
7.	Atropine (Hyoscyamine)
8.	Adenosine Triphosphatases (ATPase)
9.	digitoxigenin-galactose
9 Drugs and Important Bio-Agents and 10 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>